10:20 AM EDT, 06/24/2024 (MT Newswires) -- ChromaDex ( CDXC ) said Monday a phase 2 trial showed the "promising effects" of nicotinamide riboside supplementation in people with peripheral artery disease.

The data showed benefits of nicotinamide riboside like an improvement in treadmill walking time and a statistically significant and clinically meaningful improvement in the six-minute walking distance in people with the disease, the company said.

The results require confirmation in a larger trial, according to the statement.

Price: 2.83, Change: +0.10, Percent Change: +3.66